Sun screen with disodium phenyl dibenzimidazole tetrasulfonate and terephthalylidene dicamphor sulfonic acid

Abstract

The invention relates to a cosmetic preparation containing a) the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

Description

[0001] Description

[0002] Sunscreen with disodium phenyldibenzimidazoletetrasulfonate and terephthalylidene dicamphorsulfonic acid

[0003] The present invention relates to a cosmetic preparation containing the triethanolamine salt of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) and the triethanolamine salt of terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0004] The trend away from a refined pallor toward "healthy, athletically tanned skin" has been unbroken for years. To achieve this, people expose their skin to sunlight, as this triggers pigment formation in the form of melanin. However, the ultraviolet radiation from sunlight also has a damaging effect on the skin. In addition to acute damage (sunburn), long-term damage such as an increased risk of skin cancer occurs with excessive exposure to light in the UVB range (wavelength: 280-320 nm). Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) also leads to a weakening of the elastic and collagen fibers of the connective tissue. This causes numerous phototoxic and photoallergic reactions and results in premature skin aging.

[0005] To protect the skin, a number of sunscreen filter substances have been developed that can be used in cosmetic preparations. These UVA and UVB filters are summarized in most industrialized countries in the form of positive lists, such as Annex 7 of the Cosmetics Regulation.

[0006] However, the large number of commercially available sunscreens should not obscure the fact that these state-of-the-art preparations have a number of disadvantages.

[0007] For many years, there has been a steadily growing demand for UV-A filter substances. This is due in no small part to numerous government regulations that require a balanced ratio of UV-A and UV-B protection in sunscreens. However, the number of UV-A filters available in cosmetics is very limited. Oil-soluble compounds such as butyl methoxydibenzoylmethane or diethylamino hydroxybenzoyl hexyl benzoate are primarily used.

[0008] To achieve particularly high UV protection, however, it is necessary to incorporate UV-A filters into the aqueous phase as well. For this purpose, around the turn of the millennium, the company Symrise developed the compound disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) as a water-soluble UV-A filter. However, this substance has the disadvantage of fluorescing strongly in certain wavelength ranges. This effect was first observed in nightclub visitors who sparkled bluish under "black light." This fluorescence phenomenon initially made the UV filter unusable for further use in cosmetics, and a number of research projects were launched to resolve the problem. Symrise found an initial promising solution in the use of troxerutin. This solution was successfully patented under EP2185126.

[0009] Although the combination with troxerutin resulted in a significant reduction in fluorescence, a weak residual fluorescence remained, further hindering the use of disodium phenyl dibenzimidazole tetrasulfonate in cosmetics. There are also reasons to avoid troxerutin, considering the cost of such a preparation and its tolerability (allergic reactions cannot be ruled out in individual cases).

[0010] It was therefore the object of the present invention to solve this problem of the prior art and to further reduce the fluorescence of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in cosmetic preparations without having to use troxerutin or to reduce its amount used.

[0011] Surprisingly, the problem is solved by a cosmetic preparation containing a) the triethanolamine salt of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0012] Although the skilled person is familiar with EP2185126, there is also DE10 2022 203499.6, which was not yet published at the time of the present application, these documents could not point the way to the present invention. It is advantageous according to the invention if the preparation according to the invention contains disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in a concentration of 0.1 to 5% by weight, based on the total weight of the preparation. A content of 0.5 to 3% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0013] This compound is neutralized with triethanolamine during the preparation process.

[0014] Furthermore, the advantageous embodiments of the present invention are characterized in that the preparation contains terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) in a concentration of 0.1 to 3% by weight, based on the total weight of the preparation. A content of 1 to 3% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0015] This sulfonic acid is also neutralized with triethanolamine during the preparation process.

[0016] Furthermore, it is advantageous in the sense of the present invention if the weight ratio of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) to terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 0:3 to 1:1.

[0017] It is advantageous according to the invention if the preparation according to the invention is in the form of an aqueous or aqueous-alcoholic gel.

[0018] If the product is an aqueous gel, the aqueous phase of the neutralized disodium phenyldibenzimidazole tetrasulfonate is incorporated into the neutralized aqueous phase of terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid). In other words, two aqueous phases, each containing one of the sulfonic acids, are prepared, neutralized separately with triethanolamine, and then combined to form an aqueous preparation.

[0019] Advantageous embodiments of the present invention are characterized in that the preparation is free from 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), homomenthyl salicylate (homosalate), 2-ethylhexyl 4-methoxycinnamate, 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthraliate), and sulisobenzone (INCI: Benzophenone-4). Furthermore, it is advantageous according to the invention if the preparation according to the invention is free from polyethylene glycol, polyethylene glycol ethers, and polyethylene glycol esters (so-called PEG derivatives), is free from polyacrylates, mineral oils, and silicone oils, and is free from parabens, methylisothiazolinone, chloromethylisothiazolinone, and DMDM ​​hydantoin.

[0020] For the cosmetic preparation according to the invention or the method according to the invention, it is particularly advantageous if the preparation contains 2-phenylbenzimidazole-5-sulfonic acid salts.

[0021] In such a case, the preferred embodiments according to the invention are characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonic acid salts in a concentration of 0.1 to 8% by weight, based on the total weight of the preparation.

[0022] Furthermore, it is advantageous according to the invention if the sodium salt or the triethanolamine salt is used as 2-phenylbenzimidazole-5-sulfonic acid salt.

[0023] According to the invention, it is advantageous if the preparation contains one or more compounds selected from the group consisting of xanthan gum (INGI: Xanthan Gum), welan gum (INGI: Welan Gum), gelan gum (INGI: Gelan Gum), sclerotium gum (INGI: Scerotium Gum), cellulose, and / or cellulose derivatives. Examples of advantageous celluloses and cellulose derivatives include microcrystalline cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, methoxyethyl cellulose, methoxypropyl cellulose, and carboxymethyl cellulose.

[0024] Furthermore, it is particularly advantageous according to the invention if the preparation according to the invention contains ethylhexylglycerol and / or 4-hydroxyacetophenone.

[0025] If the preparation according to the invention contains only ethylhexylglycerol and no 4-hydroxyacetophenone, the advantageous use concentration according to the invention is from 0.1 to 0.5% by weight, based on the total weight of the preparation.

[0026] If the preparation according to the invention contains only 4-hydroxyacetophenone and no ethylhexylglycerol, the advantageous use concentration according to the invention is from 0.1 to 0.6% by weight, based on the total weight of the preparation.

[0027] If the preparation according to the invention contains both ethylhexylglycerol and 4-

[0028] Hydroxyacetophenone, the advantageous use concentration according to the invention for ethylhexylglycerol is from 0.1 to 0.5% by weight and for 4-hydroxyacetophenone from 0.1 to 0.6% by weight, in each case based on the total weight of the preparation.

[0029] It is furthermore advantageous according to the invention if the preparation contains silica and / or glass spheres with a particle diameter of 5 to 120 pm.

[0030] If the preparation according to the invention contains a lipophilic phase, it is furthermore advantageous according to the invention if the preparation or process is characterized in that the preparation contains 2-(4'-(diethylamino)-2'-hydoxybenzoyl)-benzoic acid hexyl ester, 2,4,6-tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone) and / or 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INGI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine).

[0031] Furthermore, in such a case, it is advantageous according to the invention if the preparation or process is characterized in that the preparation contains 2, 4, 6-tribiphenyl-4-yl-1,3,5-triazine (INGI: Tris-Biphenyl Triazine), 2-ethoxyethyl-(2Z)-2-cyano-2-[3-(3-methoxypropylamino)cyclohex-2-en-1-ylidene]acetate (INCI: Methoxypropylamino Cyclohexylidene Ethoxyethylcyanoacetate) and / or the compound contains.

[0032] Furthermore, in such a case it is advantageous according to the invention if the preparation contains lauryl glucoside and / or decyl glucoside.

[0033] Advantageous embodiments of the present invention are characterized in that the preparation contains one or more compounds selected from the group of alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, ß-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1,16-dicarboxylic acid, glyceryl glycose, (2-hydroxyethyl)urea, vitamin E or its derivatives, hyaluronic acid and / or its salts and / or licochalcone A. According to the invention, it is advantageous if the preparation contains one or more alkanediols from the group of compounds 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, and 2-methyl-1,3-propanediol. According to the invention, the use of 1,2-hexanediol is preferred.

[0034] It is furthermore advantageous in the sense of the present invention if the preparation according to the invention contains one or more perfume substances selected from the group of the compounds limonene, citral, linalool, alpha-isomethyl ionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, alpha-amyl cinnamaldehyde, alpha-methyl ionone, amyl cinnamaldehyde, butylphenyl methylpropional cinnamal, amyl salicylate, amyl cinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl methylpropional, cardamom oil, cedrol, cinnamal, Cinnamyl Alcohol, Citronellyl Methyl Crotonate, Citron Oil, Coumarin, Diethyl Succinate, Ethyllinalool, Eugenol, Evernia Furfuracea Extract, Evernia Prunastri Extract, Farnesol, Guaiac Wood Oil, Hexyl Cinnamal, Hexyl Salicylate, Hydroxycitronellal, Lavender Oil, Lemon Oil, Linayl Acetate, Tangerine Oil, Menthyl PCA,Contains methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethyl citrate and / or vanillin.

[0035] According to the invention, the preparation according to the invention advantageously contains film formers. Film formers within the meaning of the present invention are substances of various compositions that are characterized by the following property: If a film former is dissolved in water or other suitable solvents and the solution is then applied to the skin, it forms a film after the solvent evaporates, which essentially serves to fix the light filters to the skin and thus increase the water resistance of the product.

[0036] These film formers can, for example, be selected from the group of polymers based on polyvinylpyrrolidone (PVP) or are copolymers of polyvinylpyrrolidone, for example the PVP hexadecene copolymer and the PVP eicosene copolymer, which are available under the trade names Antaron V216 and Antaron V220 from GAF Chemicals Cooperation.

[0037] However, according to the invention it is preferred if corn starch, malodextrin and / or pullulan are used for this purpose.

[0038] Last but not least, the preparations and methods according to the invention are characterized in that the preparation is free of troxerutin. Comparative experiment

[0039] The following formulations were prepared and their fluorescence properties were investigated:

[0040] The fluorescence (color intensity at 365 and 312 nm) was determined as follows:

[0041] First, 3.0 mL of the samples are transferred into glass Petri dishes (diameter 5 cm).

[0042] The Petri dishes are then placed individually on a dark surface. A standard DSLR or DSLM camera is mounted at a height of 30 cm (here a Canon PowerShot SX540 HS). A UV lamp is mounted in the same way (here a VL-6.LM 365 / 312 2x6W UV lamp 230V EU; set to 365 and 312 nm, respectively). The images in these examples were taken with the following camera settings and are for guidance only: ISO 400; F = 4.0; self-timer 25s. The images are analyzed using a program that can separate color channels. In this case, GIMP 2.10.28 was used. Using a histogram, the color channels of the images can be separated into RGB colors. The analyzed area of ​​the images must be selected appropriately so that only the contents of the Petri dishes are separated in the histogram. The fluorescence value is determined based on the blue value at 365 or 312 nm excitation wavelength.Conclusion: The fluorescence and the blue value are reduced by the presence of terephthalylidenedicamphorsulfonic acid and by the presence of triethanolamine.

[0043] Examples

[0044] The following examples are intended to illustrate the present invention without limiting it. Unless otherwise stated, all quantities, proportions, and percentages are based on the weight and the total amount or the total weight of the preparations.

Claims

Patent claims 1 . Cosmetic preparation containing a) the triethanolamine salt of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

2. Cosmetic preparation according to claim 1, characterized in that the preparation contains disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in a concentration of 0.1 to 5% by weight, based on the total weight of the preparation.

3. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) in a concentration of 0.1 to 3% by weight, based on the total weight of the preparation.

4. Cosmetic preparation according to one of the preceding claims, characterized in that the weight ratio of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) to terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 0:3 to 1:

1.

5. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation is in the form of an aqueous or aqueous-alcoholic gel.

6. A process for producing an aqueous cosmetic gel according to any one of the preceding claims, characterized in that the terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is neutralized in a first aqueous phase by means of triethanolamine and is then combined with a separately prepared second aqueous phase in which the disodium phenyldibenzimidazole tetrasulfonate has been neutralized with triethanolamine.

7. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation is free from 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), homomenthyl salicylate (homosalate), 4-methoxycinnamic acid (2-ethylhexyl) ester, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthraliate) and sulisobenzone (INCI: Benzophenone-4).

8. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation is free from polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (so-called PEG derivatives), free is free from polyacrylates, mineral oils and silicone oils and is free from parabens, methylisothiazolinone, chloromethylisothiazolinone and DMDM ​​hydantoin.

9. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonic acid salts.

10. Cosmetic preparation or method according to claim 9, characterized in that the preparation contains 2-phenylbenzimidazole-5-sulfonic acid salts in a concentration of 0.1 to 8% by weight, based on the total weight of the preparation. 1 1. Cosmetic preparation or method according to claim 10, characterized in that the sodium salt or the triethanolamine salt is used as 2-phenylbenzimidazole-5-sulfonic acid salt.

12. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation contains one or more compounds selected from the group xanthan gum (INGI: Xanthan Gum), welan gum (INGI: Welan Gum), gelan gum (INGI: Gelan Gum), sclerotium gum (INGI: Scerotium Gum), cellulose and / or cellulose derivatives.

13. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation contains ethylhexylglycerin and / or 4-hydroxyacetophenone.

14. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation contains silica and / or glass spheres with a particle diameter of 5 to 120 pm.

15. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation contains corn starch, malodextrin and / or pullulan.

16. Cosmetic preparation or method according to one of the preceding claims, characterized in that the preparation is free from troxerutin.

Images